EPA cancels pesticide shown to be harmful to unborn babies

Overall reaction to DCPA ban

• Many welcome the ban, especially given fetal toxicity and birth-defect risks.
• Strong frustration that EPA classified DCPA as a likely carcinogen decades ago yet only now issued an emergency stop-use order.
• Some worry that prohibiting sale may push remaining stock to weaker-regulation countries, citing historical precedents with other pesticides.

Glyphosate comparison and pesticide risk

• Some argue glyphosate should be next, citing repeated patterns: chemicals approved, widely used, then later restricted (DDT, BPA, PFCs, DCPA).
• Others say glyphosate is not comparable: toxicology data suggest relatively low acute toxicity, and classification as “probably carcinogenic” is still debated.
• Distinction raised between pure glyphosate and commercial formulations whose surfactants/adjuvants may be more toxic.
• A meta‑analysis linking glyphosate-based herbicides to non‑Hodgkin lymphoma is mentioned as “compelling” evidence, while others point to sources describing overall low risk.

Regulation: EPA, IARC, and timelines

• Clarification that EPA and IARC use different classification systems and do not bind each other.
• EPA’s “likely carcinogen” category is described as based mainly on animal and mechanistic evidence with limited or no clear human data.
• Some note the U.S. acts more reactively, reopening pesticide reviews roughly every 15 years; calls for more frequent and better-funded re-evaluations.
• Others ask why re-checking is periodic rather than triggered only by new data.

US vs EU regulatory philosophy

• One view: U.S. is more libertarian and reactive; Europe more precautionary and protective of citizens.
• Counterview: EU regulation often protects domestic agriculture/economic interests rather than people; skepticism that Europe is truly safer overall.
• Examples surface on both sides (pesticide bans, antibiotics access) without clear resolution.

Externalities and moral limits of pricing harm

• Debate on whether harms to fetuses/unborn children could be “priced in” as an externality vs being inherently moral/non‑monetizable.
• Some propose actuarial-style costing (medical costs, lost earnings, disability-adjusted life years).
• Others stress practical difficulties: attribution, slow or subtle harms, and unmeasurable losses (e.g., reduced IQ, lost potential).
• Several argue some harms justify outright bans rather than taxes or price adjustments.

Language: “unborn babies” vs “fetuses”

• Disagreement over terminology: some see “unborn babies” as politically loaded, typically used by anti‑abortion advocates.
• Others argue it’s a straightforward humanizing term with historical analogs and that focusing on wording here distracts from pesticide safety.
• Concern that language shapes public attitudes about abortion and fetal status, so neutral terms like “fetus” are preferred by some.